Gene editing provides us with an unprecedented ability to improve the nutritional quality of crops without altering their growth or yield” ...

Equities researchers at Zacks Research upped their Q2 2025 earnings estimates for CRISPR Therapeutics in a report issued on ...

This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in his ISA. The post Could buying this gene-editing penny stock at $1 make me ...

Pneumocystis jirovecii pneumonia (PJP) is the most common fungal pneumonia in children. But current diagnostic methods can take days an require an invasive bronchoscopy procedure. Now, a new ...

Spread the love Table of Contents Introduction Methodology Top 10 Biotech Giants Rising Stars (11-25) Innovators and ...

The sequence contained a promising new genetic tool for modifying DNA, a CRISPR. Editas Medicine, a Massachusetts-based ...

Analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for CRISPR Therapeutics in a report ...

On track to declare two in vivo editingdevelopment candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present ...

Tulane University researchers have developed a test that diagnoses Pneumocystis jirovecii pneumonia (PJP) — a ...

Where some saw an imperfect compromise, other attendees apparently left the talks in disgust. In published reports, for ...

Editas Medicine, Inc.’s EDIT share price has surged by 16.48%, which has investors questioning if this is right time to sell.

The inducement grant consisted of time-based restricted stock units (“RSUs”) for 32,600 shares of Intellia’s common stock, with one-third of such RSUs vesting on March 1, 2026, 2027 and 2028.